No CrossRef data available.
Published online by Cambridge University Press: 06 July 2021
1 Office of the United States Trade Representative, “Statement from Ambassador Katherine Tai on the Covid-19 Trips Waiver,” May 5, 2021, https://ustr.gov/about-us/policy-offices/press-office/press-releases/2021/may/statement-ambassador-katherine-tai-covid-19-trips-waiver.
2 “Whose WTO Is It Anyway?, World Trade Organization, accessed May 20, 2021, https://www.wto.org/english/thewto_e/whatis_e/tif_e/org1_e.htm.
3 Madeline Chambers and Andreas Rinke, “Germany Rejects U.S. Proposal to Waive Patents on COVID-19 Vaccines,” Reuters, May 6, 2001, https://www.reuters.com/business/healthcare-pharmaceuticals/germany-opposes-us-plan-waive-patents-covid-19-vaccines-2021-05-06/.
4 David Ljunggren and Steve Scherer, “Canada Ready to Discuss COVID-19 Vaccine IP Waiver, ‘Not Interfering or Blocking’—Trudeau,” Reuters, May 7, 2021, https://www.reuters.com/world/americas/canada-willing-discuss-covid-19-vaccine-ip-waiver-statement-2021-05-07/; “China Backs Talks on Intellectual Property Waiver for COVID Vaccines,” Reuters, May 13, 2021, https://www.reuters.com/world/china/china-backs-talks-intellectual-property-waiver-covid-vaccines-2021-05-13/; Silvia Amaro, “EU Is ‘Ready’ to Talk about Waiving Patent Protections on Covid Vaccines, after U.S. Backs Move,” CNBC, May 6, 2021, https://www.cnbc.com/2021/05/06/covid-vaccine-eu-ready-to-talk-wave-of-ip-rights-after-us-backs-move.html.
5 Heinrichs, Melisa J. and Owens, Gary M., “Where Generics and Biologics Meet,” American Health & Drug Benefits 1, no. 5 (2008): 21–26Google ScholarPubMed, at 21.
6 Laura Smith-Spark, “Rich Nations Urged to Share Vaccine Knowledge as WTO Debates Waiving Patents,” CNN, May 5, 2021, https://edition.cnn.com/2021/05/05/world/covid-19-vaccine-patents-wto-intl/index.html.